MedTrace Logo

Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage

NCT00553423 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2007-11-05

No results posted yet for this study

Summary

To evaluate the role of lactulose in prevention of clinically overt hepatic encephalopathy (HE) in the setting of acute upper gastrointestinal bleeding in cirrhotic patients

Conditions

  • Hepatocerebral Encephalopathy
  • Portal-Systemic Encephalopathy
  • Encephalopathy, Hepatic
  • Encephalopathy, Hepatocerebral

Interventions

DRUG

Lactulose

Lactulose 30 ml q6h for 48 hrs

DRUG

Placebo

Placebo 30 ml q6hrly for 48 hrs

Sponsors & Collaborators

  • Aga Khan University

    lead OTHER

Principal Investigators

  • Shahid Majid, FCPS · Aga Khan University

  • Mohammad Salih, FCPS · Aga Khan University

  • Shahid Ahmed, FCPS · Aga Khan University

  • Wasim Jafri, FCPS · Aga Khan University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Completion
2008-11-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00553423 on ClinicalTrials.gov